Genomic Solutions Q3 Losses Narrow, Beat Expectations | GenomeWeb

NEW YORK, Oct 24 – Genomic Solutions said Tuesday its third quarter losses narrowed significantly, beating Wall Street’s expectations by 5 cents.

The company reported pro forma net losses of $869,000, or 3 cents per share, compared with a net loss of $3.9 million, or $1.31 per share, in the year-earlier period, including a $1.2 million non-cash common stock warrant charge. Excluding that charge, third-quarter 1999 losses were 92 cents per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.